Evidence map›Paper›PMID 38371067›Full record

ArticleCureus2024

COVID-19 Vaccination Rates and Predictors of Uptake Among Adults With Coronary Heart Disease: Insight From the 2022 National Health Interview Survey.

Victor C Ezeamii, Victor C Ofochukwu, Charity Iheagwara, Tracy Asibu, Oluwatoyin Ayo-Farai, Yonas H Gebeyehu, Eunice O Kaglo, Moses C Odoeke, Olaoluwa M Adeyemi, Hameed O Shittu and 1 more

Open access · diamondAbstract read
In one paragraph

Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Victor C EzeamiiPublic Health, Jiann-Ping Hsu College of Public Health, Georgia Southern University, Statesboro, USA.
Victor C OfochukwuMedicine, Ebonyi State University, Abakaliki, NGA.
Charity IheagwaraInfectious Diseases, Saint Michael's Medical Center, Newark, USA.
Tracy AsibuBiomedical Informatics, University of Texas Health Science Center at Houston, Houston, USA.
Oluwatoyin Ayo-FaraiEpidemiology and Public Health, Jiann-Ping Hsu College of Public Health, Georgia Southern University, Statesboro, USA.
Yonas H GebeyehuMedicine, Addis Ababa University, Addis Ababa, ETH.
Eunice O KagloGeneral Practice, Southwestern University School of Medicine, Calgary, CAN.
Moses C OdoekeInternal Medicine, Al Ruwaydah General Hospital, Riyadh, SAU.
Olaoluwa M AdeyemiInternal Medicine, Afe Babalola University, Ado, NGA.
Hameed O ShittuInternal Medicine, Federal Medical Centre, Abeokuta, NGA.
Okelue E OkobiFamily Medicine, Larkin Community Hospital Palm Springs Campus, Miami, USA.
Addis Ababa University · ETSaint Michael's Medical Center · USVirtua Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCOVID-19 has become a burden to all nations across the globe, and vaccination currently remains the most effective means of fighting the SARS-COV-2 pandemic. From the time of approval and subsequent distribution of the various COVID-19 vaccines, nearly 72.3% (5.5 billion) of the globe's population have been vaccinated, leaving slightly more than a quarter of the globe's population at risk. With the approval and availability of booster vaccine dosages to individuals with chronic conditions, including coronary heart disease (CHD), it is vital to comprehend the factors underlying the uptake of COVID-19 vaccination in such subgroups. Further, the American Heart Association recommends vaccination against COVID-19 in populations with coronary heart disease (CHD). This is because they are more likely to experience severe outcomes due to COVID-19 infection. This study assesses the uptake of COVID-19 vaccines as well as predictors of its uptake.

methodsUsing the 2022 survey data from the National Health Interview Survey (NHIS), 1,708 adults ≥ 40 years with CHD who responded yes/no to whether they had received the vaccine were identified. A Pearson's chi-square test was used to ascertain differences among those who had received the vaccine and those who had not. A logistic regression (multivariate regression) was used to evaluate predictors of COVID-19 vaccination.

resultsAbout 1,491/1,708 (86.8%) adults ≥ 40 years reported being vaccinated against COVID-19. Among them, 1,065/1,491 (68.4%) had received more than two vaccination doses. The predictors of COVID-19 vaccination were older age (odds ratio (OR): 2.01 (95% confidence interval (CI): 1.40-2.89), p < 0.001), ratio of family income to poverty threshold of 1 and above (OR: 2.40 (95% CI: 1.58-3.64), p < 0.001), having a college degree (OR: 3.09 (95% CI: 1.85-5.14), p < 0.001), and being insured (OR: 3.26 (95% CI: 1.03-10.26), p = 0.044).

conclusionThe findings of the study have indicated that 68.4% of adults 40 years and above with CHD have been vaccinated against COVID-19 and have received more than two doses of vaccines. More than half have followed recommendations and have received booster doses of the vaccine. Old age (above 40 years) and a higher socioeconomic class are associated with being more likely to follow COVID-19 vaccination guidelines. Despite the higher vaccination rate of 68.4% in the adults with heart diseases group, strategies for improving booster vaccine awareness alongside accessibility are needed to enhance additional dosage uptake, protect them against novel COVID-19 variants, and ensure the development of sustained immunity.

Indexed as

coronary heart diseasecovid-19older agepreventionvaccine

Identifiers

PMID38371067
PMCPMC10873900
OpenAlexW4391011928

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.